Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks

Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor (EGFR) regulate cellular homeostatic processes. EGFR activates downstream signaling cascades that promote tumor cell survival, proliferation and migration. Dysregulation of EGFR signaling as a consequence of overexpression...

Full description

Bibliographic Details
Main Authors:	German G. Gomez, Jill Wykosky, Ciro Zanca, Frank B. Furnari, Webster K. Cavenee
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2013-12-01
Series:	Cancer Biology & Medicine
Subjects:	Epidermal growth factor receptor microRNA tyrosine kinase inhibitors therapeutic resistance
Online Access:	http://www.cancerbiomed.org/index.php/cocr/article/view/616

Similar Items

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs
by: Zhang H, et al.
Published: (2020-06-01)

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
by: Narayan Shivapurkar, et al.
Published: (2017-10-01)

Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations
by: Wenxing DU, et al.
Published: (2019-09-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis
by: Anand Singh, et al.
Published: (2021-06-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
by: Chang CY, et al.
Published: (2021-03-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

The Relationship between EGFR Mutations and Response and Prognosis of Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer
by: Xuebing LI, et al.
Published: (2008-04-01)

MicroRNAs in central nervous system disorders: current advances in pathogenesis and treatment
by: Mona Hussein, et al.
Published: (2021-03-01)

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report
by: Satoshi Muto, et al.
Published: (2020-11-01)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
by: Fang Wang, et al.
Published: (2019-03-01)

Assessment of the tumor malignancy after immunotherapy combined with EGFR-TKIs drug treatment of EGFR-mutant advanced non-small cell lung cancer
by: Lu Bai1, et al.
Published: (2017-04-01)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
by: Sho Watanabe, et al.
Published: (2021-03-01)

Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
by: Carlo Buonerba, et al.
Published: (2019-08-01)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
by: Zhou S, et al.
Published: (2019-10-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
by: Wu JX, et al.
Published: (2018-10-01)

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
by: Tri Le, et al.
Published: (2019-03-01)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI ) rechallenge in small cell transformation after EGFR-TKI failure: a case report
by: Lee S, et al.
Published: (2018-07-01)

The path to microRNA therapeutics in psychiatric and neurodegenerative disorders
by: Anthony WS Chan, et al.
Published: (2012-05-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
by: Lee CS, et al.
Published: (2021-08-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)

MicroRNA as Novel Strategies for Cancer Treatment
by: Hossein Javdani, et al.
Published: (2018-02-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
by: Chen-Yu Hu, et al.
Published: (2019-12-01)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis
by: Wenxian Wang, et al.
Published: (2018-10-01)

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report
by: Francesca Aroldi, et al.
Published: (2014-07-01)

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
by: Duan H, et al.
Published: (2018-04-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
by: Chang H, et al.
Published: (2016-08-01)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
by: Li Sun, et al.
Published: (2021-01-01)

Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer
by: Baodong LIU, et al.
Published: (2016-12-01)